Literature DB >> 709874

A new approach to determining cholinesterase activities in samples of whole blood.

K B Augustinsson, H Eriksson, Y Faijersson.   

Abstract

A sensitive method, especially suitable for clinical laboratories, for the routine determination of cholinesterase activities in whole blood is presented. This method is based on the hydrolysis of propionylthiocholine and the spectrophotometric determination of the thiocholine produced by reaction with 4,4'-dithiodipyridine. The reaction product 4-thiopyridone has an absorption maximum at 324 nm, so that measurement in the presence of hemoglobin is possible. Propionylthiocholine is used at the substrate for both plasma butyrylcholinesterase and erythrocyte acetylcholinesterase. These two enzymes, in the relative amounts at which they are present in human blood, split this ester at about the same rate. Consequently, a first determination gives the total activity of which each individual activity is about 50%. A second determination in the presence of a selective inhibitor ("Astra 1397") for plasma butyrylcholinesterase gives the activity of the erythrocyte acetylcholinesterase. The difference between the two values represents the activity of the plasma enzyme. The validity of the method and the reliability of the results were checked with each blood sample in two ways: (1) by determining the activities of whole blood with an earlier gasometric technique which uses blood sample dried on filter paper; and (2) by measuring the activities in separated plasma and erythrocyte hemolysate eith propionylthiocholine as the substrate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709874     DOI: 10.1016/0009-8981(78)90322-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

1.  Protection of guinea pigs against soman poisoning with ferrocene carbamate.

Authors:  N Karlsson; R Larsson; G Puu
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

2.  Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects.

Authors:  Y Aden-Abdi; T Villén; O Ericsson; L L Gustafsson; M L Dahl-Puustinen
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

3.  Spontaneous recovery of cholinesterases after organophosphate intoxication: effect of environmental temperature.

Authors:  P Honkakoski; R Ryhänen; M Harri; P Ylitalo; O Hänninen
Journal:  Bull Environ Contam Toxicol       Date:  1988-03       Impact factor: 2.151

4.  Blood cholinesterase activities of flower garden workers after exposure to organophosphates.

Authors:  R Rhyänen; J Liesivuori; M Närhi; E Puhakainen; O Hänninen
Journal:  Bull Environ Contam Toxicol       Date:  1984-03       Impact factor: 2.151

5.  Treatment of organophosphate poisoning in pigs: antidote administration by a new binary autoinjector.

Authors:  A Göransson-Nyberg; G Cassel; T Jeneskog; L Karlsson; R Larsson; M Lundström; S A Persson
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

6.  Pharmacokinetics of bambuterol during oral administration to asthmatic children.

Authors:  H Ahlström; J Alvero; R Alvero; R Espos; L Fajutrao; J Herrera; B Kjellman; J Kubista; C Leviste; P Meyer; G Oldaeus; A Siricururat; P Vichyanond; G Wettrell; E Wong; L Laxmyr; L Nyberg; H Olsson; E Weibull; J Rosenborg
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

7.  Cholinesterase levels in blood plasma and erythrocytes from calves, normal delivering cows and cows suffering from parturient paresis.

Authors:  K Forslund; C Björkman; M Abrahamsson
Journal:  Acta Vet Scand       Date:  1983       Impact factor: 1.695

8.  Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults.

Authors:  J Rosenborg; P Larsson; L Nyberg
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

9.  Pharmacokinetics of bambuterol in healthy subjects.

Authors:  L Nyberg; J Rosenborg; E Weibull; S Jönsson; B M Kennedy; M Nilsson
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.